Float Short %

9.28

Margin Of Safety %

Put/Call OI Ratio

0.08

EPS Next Q Diff

0.03

EPS Last/This Y

EPS This/Next Y

1.87

Price

56.08

Target Price

73.18

Analyst Recom

1.18

Performance Q

-4.15

Relative Volume

0.86

Beta

2.29

Ticker: RYTM

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-01-23	RYTM	58.47	0.08	0.00	7284
2025-01-24	RYTM	57.89	0.08	1.00	7310
2025-01-27	RYTM	56.43	0.08	0.00	7312
2025-01-28	RYTM	56.75	0.08	0.00	7326
2025-01-29	RYTM	57.18	0.08	0.00	7361
2025-01-30	RYTM	59.32	0.08	0.00	7363
2025-01-31	RYTM	59.41	0.08	0.00	7405
2025-02-03	RYTM	59.45	0.08	0.00	7400
2025-02-04	RYTM	59.94	0.08	0.00	7406
2025-02-05	RYTM	60.97	0.08	3.75	7413
2025-02-06	RYTM	60.01	0.08	1.00	7405
2025-02-07	RYTM	59.24	0.08	0.00	7406
2025-02-10	RYTM	58.55	0.08	0.08	7409
2025-02-11	RYTM	57.62	0.08	0.00	7421
2025-02-12	RYTM	58	0.08	0.33	7419
2025-02-13	RYTM	57.2	0.08	0.00	7421
2025-02-14	RYTM	56.72	0.08	0.20	7421
2025-02-18	RYTM	57.53	0.08	0.00	7433
2025-02-19	RYTM	58.02	0.08	0.00	7428
2025-02-20	RYTM	58.18	0.08	0.07	7449
2025-02-21	RYTM	56.09	0.08	0.00	7409
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-01-23	RYTM	58.47	-5.5	-	-4.41
2025-01-24	RYTM	57.77	-5.5	-	-4.41
2025-01-27	RYTM	56.51	-5.5	-	-4.41
2025-01-28	RYTM	56.73	-5.5	-	-4.41
2025-01-29	RYTM	57.19	-5.5	-	-4.41
2025-01-30	RYTM	59.22	-5.5	-	-4.41
2025-01-31	RYTM	59.43	-5.5	-	-4.41
2025-02-03	RYTM	59.41	-4.3	-	-4.41
2025-02-04	RYTM	59.95	-4.3	-	-4.41
2025-02-05	RYTM	61.01	-4.3	-	-4.41
2025-02-06	RYTM	59.95	-4.3	-	-4.41
2025-02-07	RYTM	59.26	-4.3	-	-4.41
2025-02-10	RYTM	58.47	-4.3	-	-4.41
2025-02-11	RYTM	57.62	-4.3	-	-4.41
2025-02-12	RYTM	57.68	-4.3	-	-4.41
2025-02-13	RYTM	57.56	-4.3	-	-4.41
2025-02-14	RYTM	56.69	-4.3	-	-4.41
2025-02-18	RYTM	57.55	-4.3	-	-4.41
2025-02-19	RYTM	58.00	-4.3	-	-4.41
2025-02-20	RYTM	57.68	-4.3	-	-4.41
2025-02-21	RYTM	56.08	-4.3	-	-4.41
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-01-23	RYTM	-3.86	-3.28	9.60
2025-01-24	RYTM	-3.86	-3.28	9.60
2025-01-27	RYTM	-3.86	-2.77	9.60
2025-01-28	RYTM	-3.86	-2.77	9.95
2025-01-29	RYTM	-3.86	-2.77	9.95
2025-01-30	RYTM	-3.86	-2.77	9.95
2025-01-31	RYTM	-3.84	-2.77	9.95
2025-02-03	RYTM	-3.84	-3.05	9.95
2025-02-04	RYTM	-3.84	-3.05	9.95
2025-02-05	RYTM	-3.97	-3.05	9.95
2025-02-06	RYTM	-3.97	-3.05	9.95
2025-02-07	RYTM	-3.97	-3.05	9.95
2025-02-10	RYTM	-4.02	-2.86	9.95
2025-02-11	RYTM	-4.00	-2.86	9.95
2025-02-12	RYTM	-4.11	-2.86	9.36
2025-02-13	RYTM	-4.11	-2.86	9.36
2025-02-14	RYTM	-3.35	-2.86	9.36
2025-02-18	RYTM	-3.35	-4.84	9.36
2025-02-19	RYTM	-3.30	-4.84	9.37
2025-02-20	RYTM	-3.53	-4.84	9.37
2025-02-21	RYTM	-3.83	-4.84	9.28
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.73

Avg. EPS Est. Current Quarter

-0.8

Avg. EPS Est. Next Quarter

-0.7

Insider Transactions

-3.83

Institutional Transactions

-4.84

Beta

2.29

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

18.2

Max Drawdown 5-Year %

-92.1

Target Price

73.18

P/E

Forward P/E

PEG

P/S

30.62

P/B

307.15

P/Free Cash Flow

EPS

-4.34

Average EPS Est. Cur. Y

-4.41

EPS Next Y. (Est.)

-2.54

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-232.41

Relative Volume

0.86

Return on Equity vs Sector %

-2328.1

Return on Equity vs Industry %

-2312.5

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Rhythm Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 226

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

stock quote shares RYTM – Rhythm Pharmaceuticals Inc. Stock Price stock today

news today RYTM – Rhythm Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RYTM – Rhythm Pharmaceuticals Inc. yahoo finance google finance

stock history RYTM – Rhythm Pharmaceuticals Inc. invest stock market

stock prices RYTM premarket after hours

ticker RYTM fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: RYTM

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y